News
RXRX
7.51
-2.09%
-0.16
This Just In: Analysts Are Boosting Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Outlook for This Year
Simply Wall St · 14h ago
Cathie Wood's Ark Invest Loads Up On Tempus AI, Archer Aviation, But Sells Twist Bioscience: Here Are Key Ark Trades This Friday
Benzinga · 1d ago
Recursion Pharmaceuticals Reports Mixed 2024 Financial Results
TipRanks · 2d ago
Cathie Wood’s ARK Investment buys 653K shares of Recursion Pharmaceuticals today
TipRanks · 2d ago
Recursion Pharmaceuticals Price Target Cut to $6.00/Share From $7.00 by Leerink Partners
Dow Jones · 2d ago
Recursion Pharmaceuticals Is Maintained at Market Perform by Leerink Partners
Dow Jones · 2d ago
Leerink Partners Maintains Market Perform on Recursion Pharmaceuticals, Lowers Price Target to $6
Benzinga · 2d ago
Strong Buy Recommendation for Recursion Pharmaceuticals: Leading Techbio Innovator with Robust Financials and Strategic AI Integration
TipRanks · 2d ago
Recursion Pharmaceuticals (RXRX) Gets a Hold from TD Cowen
TipRanks · 2d ago
Recursion Pharmaceuticals projects $100M synergies in 2025 amid advancing pipeline and partnerships
Seeking Alpha · 2d ago
Recursion Pharmaceuticals price target lowered to $6 from $7 at Leerink
TipRanks · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Recursion Pharmaceuticals, DoubleVerify Holdings, Praxis Precision Medicines
Reuters · 2d ago
Recursion Pharma Shares Drop After Wider-Than-Expected 4Q Loss
Dow Jones · 2d ago
BUZZ-Nvidia-backed Recursion Pharmaceuticals falls on bigger-than-expected Q4 loss
Reuters · 2d ago
Recursion Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 2d ago
Morning Movers: Bloom Energy higher following quarterly results
TipRanks · 2d ago
Pre-Market Most Active for Feb 28, 2025 : NVDA, TSLL, IBIT, SMCI, RXRX, SQQQ, FUBO, NIO, BABA, QBTS, ACHR, IONQ
NASDAQ · 2d ago
RECURSION PHARMACEUTICALS SHARES SLIDE 12.3% PREMARKET AFTER BIGGER-THAN-EXPECTED Q4 LOSS
Reuters · 2d ago
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates
NASDAQ · 2d ago
RECURSION PHARMACEUTICALS: FILES FOR OFFERING OF UP TO $500 MLN CLASS A COMMON STOCK - SEC FILING
Reuters · 2d ago
More
Webull provides a variety of real-time RXRX stock news. You can receive the latest news about Recursion Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RXRX
More
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.